Y Intercept Hong Kong Ltd Makes New $538,000 Investment in Alto Neuroscience, Inc. $ANRO

Y Intercept Hong Kong Ltd acquired a new stake in Alto Neuroscience, Inc. (NYSE:ANRO) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 23,945 shares of the company’s stock, valued at approximately $538,000. Y Intercept Hong Kong Ltd owned 0.07% of Alto Neuroscience at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ANRO. XTX Topco Ltd grew its stake in shares of Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after purchasing an additional 5,078 shares during the last quarter. Ikarian Capital LLC raised its position in Alto Neuroscience by 368.2% during the 4th quarter. Ikarian Capital LLC now owns 515,000 shares of the company’s stock valued at $9,167,000 after purchasing an additional 405,000 shares during the last quarter. Vestal Point Capital LP lifted its holdings in Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after buying an additional 1,535,000 shares during the period. Wellington Management Group LLP purchased a new stake in Alto Neuroscience in the 4th quarter worth approximately $1,228,000. Finally, Perceptive Advisors LLC lifted its holdings in Alto Neuroscience by 1,048.5% in the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after buying an additional 1,629,027 shares during the period.

Alto Neuroscience Stock Up 6.1%

NYSE:ANRO opened at $28.10 on Tuesday. The firm’s 50-day moving average price is $22.92 and its 200-day moving average price is $20.96. The company has a market capitalization of $985.92 million, a PE ratio of -11.61 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. Alto Neuroscience, Inc. has a 1-year low of $2.53 and a 1-year high of $28.44.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). On average, equities analysts predict that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ANRO has been the topic of several research analyst reports. JonesTrading reduced their target price on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Wedbush lifted their price target on shares of Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Bank of America assumed coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price objective on the stock. Wolfe Research assumed coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating for the company. Finally, HC Wainwright restated a “buy” rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus target price of $35.25.

Alto Neuroscience Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.